Trusted Resources: News & Meetings
Latest announcements and gatherings
Regenxbio Presents Positive Initial Data From Phase I/II Trial Of Rgx-111 for the Treatment of Severe MPS I at 18th Annual World Symposium™ 2022
REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data are being presented at the 18th Annual WORLDSymposium™ from five patients in the ongoing Phase I/II trial and one patient from a single-patient Investigational New Drug (IND) application of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (MPS I).
RGX-111 is an investigational one-time gene therapy designed to deliver the gene that encodes the IDUA enzyme using the AAV9 vector. RGX-111 is administered directly to the CNS. The primary endpoint of the trial is to evaluate the safety of RGX-111. Secondary and exploratory endpoints include biomarkers of α-l-iduronidase (IDUA) enzyme activity in the cerebrospinal fluid (CSF), serum and urine, neurodevelopmental assessments, and caregiver reported outcomes.
BookmarkRelated Content
-
Gene Therapy May Reverse Hurler Syndrome, a Rare and Severe Illness in KidsGene therapy might soon offer a new opti...
-
Burden of Morbidity After Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor...Survival after blood or marrow transplan...
-
Elizabeth F. Neufeld, PhDBorn in France, Elizabeth Neufeld immigr...
-
Mucopolysaccharidosis Type I Disease Prevalence Among Patients With Idiopathic Short Stature in Saudi Arabia: Protoc...Since the underlying cause of idiopathic...
-
Mucopolysaccharidoses Type I Gene TherapyMucopolysaccharidoses type I (MPS I) is ...
-
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysacc...AVROBIO, Inc., a leading clinical-stage ...
-
Long-Term Evolution of Mucopolysaccharidosis Type I in Twins Treated With Enzyme Replacement Therapy Plus Hematopoie...Mucopolysaccharidoses (MPSs) are a heter...
Powered by
